Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Aug 24;26(13):1721-4.
doi: 10.1097/QAD.0b013e3283568884.

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

José A Mira  1 , Antonio Rivero, Ignacio de Los Santos-Gil, Luis F López-Cortés, José A Girón-González, Manuel Márquez, Dolores Merino, María del Mar Viloria, Francisco Téllez, María J Ríos-Villegas, Mohamed Omar, Antonio Rivero-Juárez, Juan Macías, Juan A Pineda; Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Affiliations
Multicenter Study

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

José A Mira et al. AIDS. .

Abstract

We assess the efficacy of pegylated interferon (peg-IFN) with ribavirin (RBV) and the predictors of sustained virological response (SVR) among HIV/hepatitis C virus genotype 4 (HCV-4)-coinfected patients. Thirty-nine (31.5%) of 124 individuals with HCV-4 achieved SVR compared with 103 (22.7%) of 453 individuals with HCV genotype 1 (P=0.046). Only interleukin-28B (IL28B) genotype CC was independently associated with SVR in HIV/HCV-4-coinfected patients. The efficacy of peg-IFN with RBV in coinfected individuals with genotype 4 is significantly higher than in those with genotype 1. IL28B CC genotype is the main predictor of response in this population.

PubMed Disclaimer

Publication types